Comparison of the SARS-CoV-2 genome with other betacoronaviruses can provide useful information on how drugs targeting other coronaviruses may improve outcomes for COVID-19 patients. The analysis was presented in a July 27 Frontiers in Cellular and Infection Microbiology article.

The SARS-CoV-2 virus is able to camouflage itself to promote viral replication, as revealed by structural details of proteins on the surface of the virus. Researchers discovered an enzyme that they believe could be an important target for antiviral drug development, according to a July 14 Nature Communications report.

Each day, we wake up hoping for positive news about vaccines and therapies to combat COVID-19. More than 70 candidate molecules are being evaluated for repurposing to treat COVID-19. This number will grow thanks to the use of new combination therapies discovered under an aggressive, disciplined, and quantitative approach to evaluating candidates called model-informed drug development.

Avacta has expanded its collaboration with Daewoong Pharmaceutical to develop stem cell treatments using Avacta's neutralizing Affimer therapy for COVID-19 patients.

Amyris and the Infectious Disease Research Institute（IDRI）have inked a binding term sheet for the development of a planned COVID-19 RNA vaccine technology platform.

Cel-Sci completed animal testing using its Ligand Epitope Antigen Presentation System（LEAPS）COVID-19 conjugate, which means the firm can now move into animal challenge studies with the live SARS-CoV-2 virus.

Novavax and Fujifilm Diosynth have signed an agreement covering the bulk manufacture of Novavax's COVID-19 vaccine candidate, Nvx-CoV2373, at Fujifilm's Morrisville, NC, facility.

New tools using surrogate viruses may be useful for rapid testing to determine whether antibodies effectively neutralize SARS-CoV-2. The viral vector-based platform approach was published in the Journal of Experimental Medicine on July 21.

Arizona State University（ASU）and the World Economic Forum have launched COVID-19 Diagnostics Commons, a project that will survey businesses and share knowledge about how to safely and effectively bring employees back to work.

Atom probe tomography and other techniques revealed that human enamel contains small chemical flaws that may affect the resiliency of the fundamental building blocks of teeth, in a study published July 2 in Nature.

Carisma Therapeutics' engineered macrophage immunotherapy has cleared an investigational new drug application through the U.S. Food and Drug Administration. The company intends to initiate a phase I clinical trial for the candidate this year.

Centara has launched the COVID-19 Clinical Outcomes database, which provides information on the results of clinical trials and observational studies on the novel coronavirus.

Synaffix and ADC Therapeutics have expanded an existing collaboration to explore additional applications of Synaffix's site-specific conjugation technologies.

Constant Therapeutics will begin a phase II clinical trial of the peptide drug TXA127 at Columbia University Irving Medical Center in New York City for the treatment of COVID-19.

Immunic has enrolled the first patients in a phase II clinical trial of Imu-838, a selective oral dihydroorotate dehydrogenase inhibitor, in combination with the neuraminidase inhibitor oseltamivir（Tamiflu）.

Comparison of the SARS-CoV-2 genome with other betacoronaviruses can provide useful information on how drugs targeting other coronaviruses may improve outcomes for COVID-19 patients. The analysis was presented in a July 27 Frontiers in Cellular and Infection Microbiology article.

AI Therapeutics has announced the start of a phase II trial for a COVID-19 treatment.

Moderna's COVID-19 vaccine candidate, messenger RNA（mRNA）-1273, has been shown to induce immune responses and control upper and lower respiratory tract infection of rhesus macaques exposed to SARS-CoV-2, according to researchers from the U.S. National Institutes of Health's（NIH）National Institute of Allergy and Infectious Diseases.

Recursion has acquired Vium to advance its technologies and grow its drug discovery pipeline of over 30 programs.

Cerevel Therapeutics and Cyclica have announced a research collaboration that will use artificial intelligence（AI）to develop new neurological medicines.

Moderna has begun a phase III clinical trial evaluating its messenger RNA（mRNA）-1273 COVID-19 vaccine candidate. The trial is expected to enroll approximately 30,000 healthy adult volunteers.

Ampio Pharmaceuticals has begun patient enrollment in its COVID-19 phase I clinical trial to evaluate its Ampion drug candidate.

Intravacc has collaborated with the Leiden Academic Center for Drug Research at Leiden University to find alternatives to the use of lab animals in vaccine quality control.

Pfizer and BioNtech have inked an agreement with the U.S. Department of Health and Human Services and the Department of Defense, as part of the federal government's Operation Warp Speed, to deliver 300 million doses of the BNT162 vaccine candidate in 2021.

Each day, we wake up hoping for positive news about vaccines and therapies to combat COVID-19. More than 70 candidate molecules are being evaluated for repurposing to treat COVID-19. This number will grow thanks to the use of new combination therapies discovered under an aggressive, disciplined, and quantitative approach to evaluating candidates called model-informed drug development.

Genome sequencing of the SARS-CoV-2 virus has revealed that the type of virus family to which the novel coronavirus belongs most likely first emerged in bats in the late 1960s, according to a new study published in Nature Microbiology on July 28.

Biopharmaceutical firm Soligenix said that preclinical immunogenicity studies of its CiVax heat stable subunit COVID-19 vaccine candidate demonstrated that both broad-spectrum antibody immunity and cell-mediated rapid onset immunity are possible using the CoVaccine HT adjuvant.

Belgian firm ExeVir Bio has closed on a 23-million euro（$26.9 million U.S.）series A financing round to support the development of its llama-derived antibody technology in treating COVID-19.

Grifols has delivered the first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials, which will be conducted this summer.

Areas of the human genome may explain the early origins of chronic immune and inflammatory diseases that develop later in life, according to a study published in Nature Communications on July 28.

Exonbio debuted its SARS-CoV-2 nucleocapsid recombinant monoclonal antibodies for the global in vitro diagnostics and research communities.

The SARS-CoV-2 virus is able to camouflage itself to promote viral replication, as revealed by structural details of proteins on the surface of the virus. Researchers discovered an enzyme that they believe could be an important target for antiviral drug development, according to a July 14 Nature Communications report.

Schrodinger and Viva Biotech have entered a strategic collaboration to expand structure-based drug discovery by generating de novo crystal structures of high-value targets.